Managing the Challenges and Opportunities of Breakthrough Therapies - - PowerPoint PPT Presentation

▶
managing the challenges and opportunities of breakthrough
SMART_READER_LITE
LIVE PREVIEW

Managing the Challenges and Opportunities of Breakthrough Therapies - - PowerPoint PPT Presentation

Oct 11, 2022 723 likes •985 views

Managing the Challenges and Opportunities of Breakthrough Therapies Workshop Prudence Scott FRACP MPhil DPhil Co-Director, Haematology/Oncology Evaluation Unit, TGA Medical Oncologist, Monash Health National Medicines Symposium, 19 May 2016

slide-1
SLIDE 1

Managing the Challenges and Opportunities of Breakthrough Therapies

Workshop

Prudence Scott FRACP MPhil DPhil Co-Director, Haematology/Oncology Evaluation Unit, TGA Medical Oncologist, Monash Health National Medicines Symposium, 19 May 2016

slide-2
SLIDE 2

Goal of this workshop

  • Foundations stream was asked to address the following:

– Evidence – Safety – Knowledge – Quality Goal: gather input, ideas, feedback on managing these key areas for medicines approved on early data

National Medicines Symposium, 19 May 2016

slide-3
SLIDE 3

Pathway to registration ‘80s, ‘90s, 2000s

Phase I, II and III clinical trials

Phase I: safety, tolerability, dose selection Phase II: safety, efficacy, dose comparisons in range of cancers Phase III: comparison with existing standard of care, used for registration

National Medicines Symposium, 19 May 2016

slide-4
SLIDE 4

Emergence of targeted therapies 2001-

Drug or other substance that interferes with specific molecules involved in cancer cell growth and survival (NCI)

  • “Driver mutations” or critical pathways
  • Specific populations
  • Biomarkers

National Medicines Symposium, 19 May 2016

slide-5
SLIDE 5

Targeted therapies

Seamless oncology trials

  • PK, PD, efficacy and safety
  • Expansion cohorts once dose-finding complete
  • Biomarker assessment

“Phase I”

needs a new name: suggestions?

  • Studies of efficacy and safety
  • Multiple open label, single arm cohorts within Phase II trials - “octopus”
  • Master protocols
  • Biomarker validation +/- test development

Phase II

  • Confirmatory

Phase III

National Medicines Symposium, 19 May 2016

slide-6
SLIDE 6

Regulatory response to unmet need

1992 FDA accelerated approval

  • unmet need
  • significant benefit over existing therapies
  • surrogate endpoint likely to predict clinical benefit
  • confirmatory data required
  • Label states in indication that approval is based on an early

endpoint and may require confirmation

National Medicines Symposium, 19 May 2016

slide-7
SLIDE 7

Accelerated approvals in Haematology/Oncology

  • Confirmation of benefit following accelerated approval

– 50% confirmed – 40% still underway – 10% benefit not confirmed

  • reasons

National Medicines Symposium, 19 May 2016

slide-8
SLIDE 8

Regulatory and advocate response to unmet need

FDA Breakthrough Designation 2012

  • Preliminary clinical data suggests a substantial benefit over existing

therapies for serious or life-threatening disease or condition

  • Access, support in clinical trial design from FDA
  • Accelerated approval not guaranteed

National Medicines Symposium, 19 May 2016

slide-9
SLIDE 9

Breakthrough designations

338 in total 137 (41%) in Haem Onc 38% granted 38% denied 20% withdrawn 201 (59%) other areas incl rare inherited disorders, ID

National Medicines Symposium, 19 May 2016

slide-10
SLIDE 10

FDA pathway approvals in Haematology/Oncology

Of 46 new drugs approved in last 4 years (30 in last 2 years!)

  • 17 accelerated approval
  • 29 regular approval
  • 19 had breakthrough designation

National Medicines Symposium, 19 May 2016

slide-11
SLIDE 11

TGA submissions in Haematology/Oncology

Registration in Australia now sought on earlier data for Haematology/Oncology products

85%

2014

75%

2015

National Medicines Symposium, 19 May 2016

slide-12
SLIDE 12

Opportunities from breakthrough designation

  • Recognition of, resulted from patient voice
  • Earlier approval addressing unmet need
  • Ensures patients have access to optimally designed trials
  • What % of patients enter clinical trials in oncology?
  • Novel clinical trial designs emerging
  • Encourages and fosters innovation e.g. small pharma
  • New ways to use big data to analyse outcomes

National Medicines Symposium, 19 May 2016

slide-13
SLIDE 13

Challenges with early approvals

  • 1. Rapid product development:

– Less known about safety and efficacy – Multiple trials still to report – Biomarker development, validation, testing may still be underway

  • Companion diagnostic vs complementary diagnostic

– Incorporation of patient-reported outcomes eg PRO-CTCAE, COA Compendium

  • 2. Collection, communication of post approval information

– Patients, clinicians, regulators, sponsors, payers – Need reporting of adverse events by all stakeholders – Effective communication of updates

  • 3. Timely completion of confirmatory trials and to act upon outcomes
  • 4. Development of systems to capture big data e.g. INFORMED

National Medicines Symposium, 19 May 2016

slide-14
SLIDE 14

Information Exchange and Data Transformation (INFORMED)

FDA Entrepreneur in Residence program

  • to support meta-analyses and other data explorations that can yield

groundbreaking scientific and regulatory insights

  • to create a big data environment comprised of aggregated datasets from:

– new drug applications (NDAs) – electronic medical records – wearable technologies – social media networks

National Medicines Symposium, 19 May 2016

slide-15
SLIDE 15

Summary of breakthrough designation era

Better drugs Better biomarkers Less information

National Medicines Symposium, 19 May 2016

slide-16
SLIDE 16

Communicating decision to approve on early data

  • 1. *Note to the Indication
  • 2. *Boxed warning in PI, equivalent in CMI
  • 3. Statement in Clinical Trials section re evidence base and further trials required to

be submitted as condition of registration (similar in CMI)

  • 4. Conditions of registration

– Confirmatory efficacy and safety Phase III study/studies – Marketing of note to the indication, boxed warning in any promotional materials

  • 5. Post approval requirements – case-by-case

– big data/real world data collection e.g. registries – key info for stakeholders – patient/doctor information cards – health professional educational material

National Medicines Symposium, 19 May 2016

slide-17
SLIDE 17

Goal of this workshop

  • Foundations stream was asked to address the following:

– Evidence – Safety – Knowledge – Quality Goal: gather input, ideas, feedback on managing these key areas for medicines approved on early data

National Medicines Symposium, 19 May 2016

slide-18
SLIDE 18

Post approval

How can we improve reporting of outcomes to the TGA?

  • immediately
  • longer term

How can registries capture efficacy and safety for medicines approved on early data? How can the TGA communicate any necessary changes effectively to stakeholders?

National Medicines Symposium, 19 May 2016

slide-19
SLIDE 19

Post approval

How can we improve reporting of

  • utcomes to the TGA?
  • immediately
  • longer term

National Medicines Symposium, 19 May 2016

slide-20
SLIDE 20

Post approval

How can the TGA communicate any necessary changes effectively to stakeholders?

National Medicines Symposium, 19 May 2016

slide-21
SLIDE 21

Post approval

How can registries capture efficacy and safety for medicines approved on early data?

National Medicines Symposium, 19 May 2016

slide-22
SLIDE 22

Post approval

Any other issues?

National Medicines Symposium, 19 May 2016

slide-23
SLIDE 23